Narayana Hrudayalaya Ltd. (NH) has announced its earnings update for Q2 FY27, revealing a significant financial performance. The consolidated operating revenue for the quarter stood at ₹28,440 Mn, marking a robust 73% year-on-year growth. The consolidated profit after tax (PAT) for the quarter was ₹3,012 Mn, reflecting a 10.6% increase compared to the same period last year.

Operational Highlights

NH’s Narayana Institute of Cardiac Sciences, Bengaluru, performed South India’s first Percutaneous Transcatheter Tricuspid Valve Replacement (TTVR) and India’s first Transcatheter Tricuspid Valve Implantation (TTVI) on a 14-year-old. The institute also achieved a high volume of cardiac surgeries, with a record 38 cases in a single day.

Financial Performance

The consolidated EBITDA for Q2 FY27 was ₹6,054 Mn, maintaining a healthy margin of 21.3%. The consolidated total borrowings less cash and bank balance and investments stood at ₹18,830 Mn, resulting in a net debt to equity ratio of 0.38. The company’s strategic initiatives and operational excellence continue to drive its financial success.

As Narayana Hrudayalaya Ltd. (NH) moves forward, the focus remains on expanding its healthcare services and maintaining its financial strength, ensuring ‘Health For All’ remains its core mission.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Narayana Hrudayalaya Ltd.

Narayana Hrudayalaya Ltd. belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Narayana falls 15.3% over three months and has not found a floor yet. The PEG stands at 4.29 — severely stretched. Any earnings miss could trigger a sharp de-rating. Thin margins at 9.0% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The stock holds at 26% of its 52-week range with RSI at 38. In other words, neither side has a clear edge right now. Revenue grows at 20.5% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Narayana Hrudayalaya Ltd..

Hikal Limited (NSE: HIKAL) has signed a multi-year contract development and manufacturing (CDMO) contract with a leading Europe-based agrochemical company. This contract follows successful process development and scale-up of a new product, marking a key commercial milestone for Hikal’s Crop Protection business.

Strategic Partnership

The contract, signed by Hikal’s Crop Protection division, covers the CDMO of a specialised agrochemical product. Hikal undertook process development and scale-up for this product. The commercial launch is expected towards the end of FY 2026–27, with volumes anticipated to grow progressively as regulatory approvals are secured across global markets.

Strengthening Capabilities

This partnership underscores Hikal’s capabilities in process development and commercialisation, demonstrating its ability to translate customer requirements into long-term manufacturing opportunities. It also strengthens Hikal’s Crop Protection business by expanding its portfolio of specialised offerings for global customers.

Forward-Looking Statement

Commenting on the development, Mr. Sameer Hiremath, Chairman & Managing Director, Hikal Limited, said: “This contract marks an important milestone for our Crop Protection business, converting nearly three years of collaborative development and scale-up into a long-term commercial partnership. It demonstrates Hikal’s ability to combine deep technical expertise with reliable manufacturing capabilities to take complex products from development to commercial supply. We are well positioned to support the planned launch and progressive expansion of supplies across global markets.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Hikal Limited

Hikal Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Hikal holds in the upper half of its 52-week range, a sign the market backs the stock. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 4 loss quarters over five years is a serious red flag — earnings quality is poor and recovery is not guaranteed. The stock holds at 60% of its 52-week range with RSI at 48. In other words, neither side has a clear edge right now. The stock holds up despite -5.4% revenue growth and a PEG of 99.00. That could signal an early turnaround. Alternatively, index flows simply support the price. Watch whether analysts revise estimates upward — that is the real signal. Check Fundamentals of Hikal Limited.

Sai Parenterals Limited (NSE: SAIPARENT) has announced its un-audited financial results for the quarter and half-year ended 30th September 2026, showcasing significant growth and strategic advancements. Revenue from operations stood at Rs. 196.1 crore, up 9.0% quarter-over-quarter (QoQ) from Rs. 179.9 crore in Q1FY27. The first half of FY27 revenue of Rs. 376.0 crore represents approximately 50% of the FY27 revenue target of Rs. 750 crore, ahead of the guided 45:55 phasing between the two halves.

Key Financial Highlights

Gross profit stood at Rs. 93.1 crore, up 26.4% QoQ, with gross margin rising to 47.5% from 40.9% in Q1FY27. The improvement reflects tighter inventory management: higher-cost inventory from earlier periods was consumed, and first-in, first-out controls were introduced on a new ERP system. EBITDA stood at Rs. 41.4 crore, up 67.4% QoQ, with EBITDA margin at 21.1% against 13.7% in Q1FY27. Despite a more than threefold sequential rise in depreciation, PAT grew 32.7% QoQ to Rs. 10.5 crore in Q2FY27.

Strategic Developments

Following shareholders’ approval of the variation in the objects of the issue, the Company has completed the acquisition of 60% stakes in Saicriti Pharma Private Limited and Prathyak Laboratories Private Limited. It invested Rs. 98.8 crore of IPO proceeds: Rs. 83.83 crore in Saicriti and Rs. 15 crore in Prathyak. The purpose for which the IPO funds were raised remains unchanged: EU-GMP compliant injectable capacity for regulated markets, and a dedicated research and development platform.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sai Parenterals Limited

Sai Parenterals Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Sai falls 12.4% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at 126.1% and profits at 111.8% CAGR. Both numbers are exceptional. The stock holds at 28% of its 52-week range with RSI at 40. In other words, neither side has a clear edge right now. Revenue grows at 126.1% and profits at 111.8% CAGR, with D/E of 0.00. Meanwhile, the stock dips 12.4% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sai Parenterals Limited.